Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of AK102 in healthy subjects
NCT04169386Phase 1Completed
- Sponsor
- Akeso, Inc.
- Start
- May 2018
- Primary completion
- Nov 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ebronucimab in hypercholesterolemia (5 arms), sponsored by Akeso, Inc. Primary endpoint: Incidence of treatment emergent Adverse Events at 12 weeks. Started May 2018; status: completed.
02
Drugs
ebronucimab
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT04169386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04169386.